08:36 AM EDT, 09/03/2025 (MT Newswires) -- Connect Biopharma ( CNTB ) said Wednesday it has completed the termination of its American Depositary Receipt program, with its ordinary shares now directly listed on the Nasdaq Global Market.

ADRs were canceled and exchanged for ordinary shares at a one-for-one ratio when the program ended on Sept. 2, the company said.

Connect remains focused on advancing its phase 2 Seabreeze STAT studies of rademikibart for asthma and COPD, it said.

Shares of the company were up over 17% in recent Wednesday premarket activity.